The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Open accessAbstract
EZ Inhibition: Missense mutations in the core constituents of the genome packaging material, chromatin, have been implicated in several of human cancers. Nucleosomes are made up of histones, and a mutation of lysine 27 (K27) to methionine in the N-terminal tail of histone variants H3.3 and H3.1 has been identified in various pediatric gliomas. Lewis et al. (p. 857 , published online 28 March; see the Perspective by Morgan and Shilatifard ) show that the polycomb enzyme complex, which can epigenetically modify K27 by addition of a methyl group—and which is often a silencing signal—is itself potently inhibited by replacement of the H3.3/3.1 K27 by methionine. The inhibition of the EZH2 subunit causes an overall reduction of K27 methylation. Methionine mutants of other methylated lysine residues in histone H3 cause similar reductions in methylation levels of the cognate lysine, altering the epigenetic profiles of such cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, tumor cells with the K27M mutation exhibit low levels of H3K27me3 and aberrant gene silencing (4,(7)(8)(9).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“act in a dominant manner to deplete H3K27 methylation by inhibiting PRC2 methyltransferase activity [5, 6]”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Additional histone H3 lysine-to-methionine mutants possess dominant gain-of-function activities [6]”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“We and others previously showed that K-to-M oncohistones transform the histone H3 proteins into potent inhibitors of specific lysine methyltransferase enzymes (4-7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies showed that the K27M mutation found in pediatric glioma is sufficient to transform histone H3 into a potent inhibitor of enzymatic activity of PRC2 (4, 5, 7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“we previously showed that H3K9M peptides are capable of inhibiting activity of SUV39H1 and G9a, two H3K9-directed methyltransferases, in vitro (7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Previously, we found that only long, unbranched hydrophobic side chains containing methionine (M) and isoleucine (I) at lysine 27 (K27M and K27I) were capable of inhibiting PRC2 in vitro and decreasing H3K27me3 when expressed ectopically in cultured cells (7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
In the citing paper
“Despite reports supporting a higher affinity of PRC2 for H3K27M as compared with wild-type H3 108-110 , H3K27M was often inversely correlated with PRC2 occupancy, challenging the idea that H3K27M sequesters PRC2 on chromatin 111,112 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [112]
In the citing paper
“Expression of the histone mutant is accompanied by a reduction in the levels of Polycomb Repressive Complex 2 (PRC2) mediated H3K27 trimethylation (H3K27me3) and this is purported to be a driving event of DIPG oncogenesis4,5.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Interestingly upon loss of H3K27me3 these nucleosomes acquire H3K27ac resulting in the formation of H3K27M-K27ac heterotypic nucleosomes4 (Figure 1D and Supplementary Fig. 5B–C).”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“As shown by our group and others, H3K27M expression is associated with increased levels of H3K27ac4,5 (Fig. 1D).”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Although still functionally active, PRC2 catalytic property toward H3K27M containing nucleosomes is strongly inhibited4.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Collectively, these results strongly indicate that H3K27M in DIPG cells does not appear to recruit or sequester EZH2 (or in general PRC2), as suggested by other studies4,6,7.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Attempts to model H3.3K27M-driven HGG formation in vivo via genetic recombination in neural progenitor/stem cells (NPCs) in the postnatal brain failed to demonstrate tumor-driving activity”
From H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas (2017) · cites this paper as Lewis et al., 2013
In the citing paper
“H3.3K27M has been shown to have gain-of-function activity inhibiting the Polycomb Repressive Complex 2 (PRC2) (Bender et al., 2013; Lewis et al., 2013), which in turn leads to a global reduction in H3K27me3 levels in primary tumors and tumor-derived primary cells.”
From H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas (2017) · cites this paper as Lewis et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., & Patel, D. J. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1338 · Cited by 1,476
Self-citationRole of the polycomb protein EED in the propagation of repressive histone marks
Margueron, R., Justin, N., Ohno, K., Sharpe, M. L., Son, J., Drury, W. J., Voigt, P., Martin, S. R., Taylor, W. R., Marco, V. D., et al. (2009) · Nature · doi:10.1038/nature08398 · Cited by 1,281
Khuong-Quang, D.-A., Buczkowicz, P., Rakopoulos, P., Liu, X.-Y., Fontebasso, A. M., Bouffet, E., Bartels, U., Albrecht, S., Schwartzentruber, J., Letourneau, L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0998-0 · Cited by 1,028
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Simon, J. A., & Lange, C. A. (2008) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2008.07.010 · Cited by 880
Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., & Copeland, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012525107 · Cited by 719
Yap, D., Chu, J., Berg, T., Schapira, M., Cheng, S., Moradian, A., Morin, R. D., Mungall, A. J. J., Meissner, B., Boyle, M., et al. (2010) · Blood · doi:10.1182/blood-2010-11-321208 · Cited by 633
A Novel Mammalian Flavin-dependent Histone Demethylase
Karytinos, A., Forneris, F., Profumo, A., Ciossani, G., Battaglioli, E., Binda, C., & Mattevi, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.003087 · Cited by 274
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 999
Chen, K.-Y. M., Bush, K. M., Klein, R. H., Cervantes, V., Lewis, N., Naqvi, A., Carcaboso, A. M., Lechpammer, M., & Knoepfler, P. S. (2020) · Communications Biology · doi:10.1038/s42003-020-1076-0 · Cited by 55
Chaouch, A., Berlandi, J., Chen, C. C. L., Frey, F., Badini, S., Harutyunyan, A. S., Chen, X., Krug, B., Hébert, S., Jeibmann, A., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.10.008 · Cited by 52
H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape
Furth, N., Algranati, D., Dassa, B., Beresh, O., Fedyuk, V., Morris, N., Kasper, L. H., Jones, D. R., Monje, M., Baker, S. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110836 · Cited by 52
Ozair, A., Bhat, V., Alisch, R. S., Khosla, A. A., Kotecha, R. R., Odia, Y., McDermott, M. W., & Ahluwalia, M. S. (2023) · Cancers · doi:10.3390/cancers15041342 · Cited by 51
Developmental origins and oncogenic pathways in malignant brain tumors
Lu, Q. R., Qian, L., & Zhou, X. (2019) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.342 · Cited by 55
Leicher, R., Ge, E. J., Lin, X., Reynolds, M. J., Xie, W. J., Walz, T., Zhang, B., Muir, T. W., & Liu, S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003395117 · Cited by 51
Self-citationHistone Lysine Methylation Dynamics Control EGFR DNA Copy-Number Amplification
Clarke, T. L., Tang, R., Chakraborty, D., Van Rechem, C., Ji, F., Mishra, S., Ma, A., Kaniskan, H. Ü., Jin, J., Lawrence, M. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0463 · Cited by 50
Noberini, R., Robusti, G., & Bonaldi, T. (2021) · FEBS Journal · doi:10.1111/febs.15707 · Cited by 51
Histone variants: the tricksters of the chromatin world
Volle, C. B., & Dalal, Y. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.006 · Cited by 54
The Genetic Signatures of Pediatric High-Grade Glioma: No Longer a One-Act Play
Diaz, A. K., & Baker, S. J. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.06.003 · Cited by 53
Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults
Rodríguez, F. J., Vizcaíno, M. A., & Lin, M. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.05.005 · Cited by 50
Drugging histone methyltransferases in cancer
Richart, L., & Margueron, R. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.009 · Cited by 51
Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM
Pathak, P., Jha, P., Purkait, S., Sharma, V., Suri, V. S., Sharma, M. C., Faruq, M., Suri, A., & Sarkar, C. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1675-z · Cited by 51
Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2
Barnash, K. D., The, J., Norris-Drouin, J. L., Cholensky, S. H., Worley, B. M., Li, F., Stuckey, J. I., Brown, P. J., Vedadi, M., Arrowsmith, C. H., et al. (2017) · ACS Combinatorial Science · doi:10.1021/acscombsci.6b00174 · Cited by 50
Ehteda, A., Simon, S., Franshaw, L., Giorgi, F. M., Liu, J., Joshi, S. M., Rouaen, J. R. C., Pang, C. N. I., Pandher, R., Mayoh, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108994 · Cited by 49
The Multiple Facets of ATRX Protein
Valenzuela, M., Amato, R., Sgura, A., Antoccia, A., & Berardinelli, F. (2021) · Cancers · doi:10.3390/cancers13092211 · Cited by 53
Histone Modifications in Stem Cell Development and Their Clinical Implications
Völker-Albert, M. C., Bronkhorst, A. J., Holdenrieder, S., & Imhof, A. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.11.002 · Cited by 52
Boileau, M., Shirinian, M., Gayden, T., Harutyunyan, A. S., Chen, C. C. L., Mikael, L. G., Duncan, H. M., Neumann, A. L., Arreba-Tutusaus, P., Jay, N. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10705-z · Cited by 53
H3K27me3-mediated silencing of structural genes is required for zebrafish heart regeneration
Ben-Yair, R., Butty, V. L., Busby, M., Qiu, Y., Levine, S. S., Goren, A., Boyer, L. A., Burns, C. G., & Burns, C. E. (2019) · Development · doi:10.1242/dev.178632 · Cited by 50
Tumour immune landscape of paediatric high-grade gliomas
Ross, J. L., Vega, J. E. V., Plant, A., MacDonald, T. J., Becher, O. J., & Hambardzumyan, D. (2021) · Brain · doi:10.1093/brain/awab155 · Cited by 46
Self-citationH3K36 methylation maintains cell identity by regulating opposing lineage programmes
Hoetker, M. S., Yagi, M., Stefano, B. D., Langerman, J., Cristea, S., Wong, L. P., Huebner, A. J., Charlton, J., Deng, W., Haggerty, C., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01191-z · Cited by 46
Wang, W., Lim, K. G., Feng, M., Bao, Y., Lee, P. L., Cai, Y., Chen, Y., Zhang, H., Marzese, D. M., Hoon, D. S. �., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0802 · Cited by 48
Emerging roles of telomeric chromatin alterations in cancer
Cacchione, S., Biroccio, A., & Rizzo, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1030-5 · Cited by 47
Kluiver, T. A., Alieva, M., van Vuurden, D. G., Wehrens, E. J., & Rios, A. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00092 · Cited by 51
Lutsik, P., Baude, A., Mancarella, D., Öz, S., Kühn, A., Tóth, R., Hey, J., Toprak, U. H., Lim, J., Nguyễn, V. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18955-y · Cited by 49
Short H2A histone variants are expressed in cancer
Chew, G.-L., Bleakley, M., Bradley, R. K., Malik, H. S., Henikoff, S., Molaro, A., & Sarthy, J. F. (2021) · Nature Communications · doi:10.1038/s41467-020-20707-x · Cited by 46
The H3K36me2 writer-reader dependency in H3K27M-DIPG
Yu, J.-R., LeRoy, G., Bready, D., Frenster, J. D., Saldaña-Meyer, R., Jin, Y., Descostes, N., Stafford, J. M., Placantonakis, D. G., & Reinberg, D. (2021) · Science Advances · doi:10.1126/sciadv.abg7444 · Cited by 51
Glial Progenitors as Targets for Transformation in Glioma
Ilkhanizadeh, S., Lau, J., Huang, M., Foster, D. J., Wong, R. A., Frantz, A., Wang, S., Weiss, W. A., & Persson, A. I. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00001-9 · Cited by 47
A histone H3K9M mutation traps histone methyltransferase Clr4 to prevent heterochromatin spreading
Shan, C., Wang, J., Xu, K., Chen, H., Yue, J., Andrews, S. J., Moresco, J. J., Yates, J. R., Nagy, P. L., Tong, L., et al. (2016) · eLife · doi:10.7554/elife.17903 · Cited by 48
Maury, E., & Hashizume, R. (2017) · Epigenetics · doi:10.1080/15592294.2016.1278095 · Cited by 50
Meers, M. P., Henriques, T., Lavender, C. A., McKay, D. J., Strahl, B. D., Duronio, R. J., Adelman, K., & Matera, A. G. (2017) · eLife · doi:10.7554/elife.23249 · Cited by 44
Marchione, D. M., Lisby, A., Viaene, A. N., Santi, M., Nasrallah, M., Wang, L., Williams, E. A., Larque, A. B., Chebib, I. A., Garcia, B. A., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0287-8 · Cited by 47
Self-citationZhang, Y., Chang, J.-F., Sun, J., Chen, L., Yang, X.-M., Tang, H.-Y., Jing, Y.-Y., Kang, X., He, Z.-M., Wu, J.-Y., et al. (2018) · Journal of Cell Science · doi:10.1242/jcs.215525 · Cited by 45
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma
Duchatel, R. J., Jackson, E. R., Parackal, S., Kiltschewskij, D. J., Findlay, I. J., Mannan, A., Staudt, D. E., Thomas, B. C., Germon, Z. P., Laternser, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170329 · Cited by 45
Chao, N., Liu, S., Liu, B.-M., Li, N., Jiang, X., & Gai, Y. (2014) · Planta · doi:10.1007/s00425-014-2128-9 · Cited by 45
Role of epigenetic mechanisms in epithelial-to-mesenchymal transition of breast cancer cells
Nickel, A., & Stadler, S. C. (2014) · Translational research · doi:10.1016/j.trsl.2014.04.001 · Cited by 44
Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone
Ali, N. M., Niada, S., Brini, A. T., Morris, M. R., Kurusamy, S., Alholle, A., Huen, D. S., Antonescu, C. R., Tirode, F., Sumathi, V. P., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5176 · Cited by 46
Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Hoffman, M., Gillmor, A. H., Kunz, D. J., Johnston, M. J. G., Nikolić, A., Narta, K., Zarrei, M., King, J., Ellestad, K. I., Dang, N. H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3441 · Cited by 47
Oncohistones: a roadmap to stalled development
Deshmukh, S., Ptack, A., Krug, B., & Jabado, N. (2021) · FEBS Journal · doi:10.1111/febs.15963 · Cited by 45
Epigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4
Mo, Y., Duan, S., Zhang, X., Hua, X., Zhou, H., Wei, H.-J., Watanabe, J., McQuillan, N., Su, Z., Gu, W. J., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1492 · Cited by 47
Diffuse Intrinsic Pontine Glioma
Hennika, T., & Becher, O. J. (2015) · Journal of Child Neurology · doi:10.1177/0883073815601495 · Cited by 46
Self-citationGliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time
Filbin, M. G., & Suvà, M. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044208 · Cited by 46
Reirradiation for diffuse intrinsic pontine glioma: a systematic review and meta-analysis
Lu, V. M., Welby, J. P., Mahajan, A., Laack, N. N. I., & Daniels, D. J. (2019) · Child s Nervous System · doi:10.1007/s00381-019-04118-y · Cited by 44
Overview of DNA methylation in adult diffuse gliomas
Aoki, K., & Natsume, A. (2019) · Brain Tumor Pathology · doi:10.1007/s10014-019-00339-w · Cited by 45
Diffuse midline glioma: review of epigenetics
Cooney, T. M., Lubanszky, E., Prasad, R., Hawkins, C. E., & Mueller, S. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03553-1 · Cited by 46
Pediatric Glioma: An Update of Diagnosis, Biology, and Treatment
Funakoshi, Y., Hata, N., Kuga, D., Hatae, R., Sangatsuda, Y., Fujioka, Y., Takigawa, K., & Mizoguchi, M. (2021) · Cancers · doi:10.3390/cancers13040758 · Cited by 44
Therapeutic Targets in Diffuse Midline Gliomas—An Emerging Landscape
Hayden, E., Holliday, H., Lehmann, R. J., Khan, A., Tsoli, M., Rayner, B. S., & Ziegler, D. S. (2021) · Cancers · doi:10.3390/cancers13246251 · Cited by 42
Oncohistones: Hijacking the Histone Code
Sahu, V., & Lü, C. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-102521 · Cited by 43
Tomita, Y., Shimazu, Y., Somasundaram, A., Tanaka, Y., Takata, N., Ishi, Y., Gadd, S., Hashizume, R., Angione, A., Piñero, G., et al. (2022) · Glia · doi:10.1002/glia.24189 · Cited by 42
Self-citationCharacteristics of gliomas in patients with somatic IDH mosaicism
Bonnet, C., Thomas, L., Psimaras, D., Bielle, F., Vauléon, É., Loiseau, H., Cartalat‐Carel, S., Meyronet, D., Dehais, C., Honnorat, J., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0302-y · Cited by 43
New Directions in the Treatment of Glioblastoma
Reitman, Z. J., Winkler, F., & Elia, A. E. H. (2018) · Seminars in Neurology · doi:10.1055/s-0038-1623534 · Cited by 45
EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma
Jenseit, A., Camgöz, A., Pfister, S. M., & Kool, M. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02382-4 · Cited by 43
Beyes, S., Bediaga, N. G., & Zippo, A. (2021) · Cancers · doi:10.3390/cancers13194969 · Cited by 44
PRC2, Chromatin Regulation, and Human Disease: Insights From Molecular Structure and Function
Liu, X., & Liu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894585 · Cited by 48
Targeting KDM4 for treating PAX3-FOXO1–driven alveolar rhabdomyosarcoma
Singh, S. V., Abu‐Zaid, A., Jin, H., Fang, J., Wu, Q., Wang, T., Feng, H., Quarni, W., Shao, Y., Maxham, L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq2096 · Cited by 43
Self-citationKMT2 Family of H3K4 Methyltransferases: Enzymatic Activity-dependent and -independent Functions
Van, H. T., Xie, G., Dong, P., Liu, Z. J., & Ge, K. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168453 · Cited by 43
The PML-Interacting Protein DAXX: Histone Loading Gets into the Picture
Salomoni, P. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00152 · Cited by 46
Ahsan, S., Raabe, E. H., Haffner, M. C., Vaghasia, A. M., Warren, K. E., Quezado, M., Ballester, L. Y., Nazarian, J., Eberhart, C. G., & Rodríguez, F. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-59 · Cited by 42
Makise, N., Sekimizu, M., Konishi, E., Motoi, T., Kubo, T., Ikoma, H., WATANABE, S.-I. I., Okuma, T., Hiraoka, N., Fukayama, M., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0140-5 · Cited by 42
Leatham-Jensen, M. P., Uyehara, C. M., Strahl, B. D., Matera, A. G., Duronio, R. J., & McKay, D. J. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1007932 · Cited by 42
Karlowee, V., Amatya, V. J., Takayasu, T., Takano, M., Yonezawa, U., Takeshima, Y., Sugiyama, K., Kurisu, K., & Yamasaki, F. (2019) · Pathobiology · doi:10.1159/000496691 · Cited by 43
Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma
Dahl, N. A., Danis, E. P., Balakrishnan, I., Wang, D., Pierce, A. M., Walker, F. M., Gilani, A., Serkova, N. J., Madhavan, K. P. C., Fosmire, S. P., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.049 · Cited by 41
Wang, J., Yang, L., Dong, C., Wang, J., Xu, L., Qiu, Y., Weng, Q., Zhao, C., Xin, M., & Lu, Q. R. (2020) · Science Advances · doi:10.1126/sciadv.aaz6477 · Cited by 43
H3K27M mutant glioma: Disease definition and biological underpinnings
Saratsis, A. M., Knowles, T., Petrović, A., & Nazarian, J. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad164 · Cited by 52
Preferential Phosphorylation on Old Histones during Early Mitosis in Human Cells
Lin, S., Yuan, Z., Han, Y., Marchione, D. M., & Garcia, B. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.726067 · Cited by 38
Self-citationLee, J. C., Solomon, D. A., & Tihan, T. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2349-9 · Cited by 45
Dang, M. T., & Phillips∥, P. C. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000545 · Cited by 41
Chromatin remodeling and epigenetic regulation of oligodendrocyte myelination and myelin repair
Koreman, E., Sun, X., & Lu, Q. R. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.11.010 · Cited by 43
An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors
Bratkowski, M. A., Yang, X., & Liu, X. (2018) · Scientific Reports · doi:10.1038/s41598-018-27175-w · Cited by 41
Choi, S. A., Lee, C., Kwak, P. A., Park, C., Wang, K., Phi, J. H., Lee, J. Y., Chong, S., & Kim, S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.012 · Cited by 40
RETRACTED ARTICLE: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma
Garancher, A., Suzuki, H., Haricharan, S., Chau, L. Q., Masihi, M. B., Rusert, J. M., Norris, P. S., Carrette, F., Romero, M. M., Morrissy, A. S., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0628-4 · Cited by 42
Self-citationRetractedEpigenetic modulators provide a path to understanding disease and therapeutic opportunityPreprint
Honer, M. A., Ferman, B. I., Gray, Z. H., Bondarenko, E. A., & Whetstine, J. R. (2024) · Genes & Development · doi:10.1101/gad.351444.123 · Cited by 44
Histone Lysine-to-Methionine Mutations Reduce Histone Methylation and Cause Developmental Pleiotropy
Sanders, D., Qian, S., Fieweger, R. A., Lü, L., Dowell, J. A., Denu, J. M., & Zhong, X. (2017) · PLANT PHYSIOLOGY · doi:10.1104/pp.16.01499 · Cited by 40
The histone variant H3.3 claims its place in the crowded scene of epigenetics
Bano, D., Piazzesi, A., Salomoni, P., & Nicotera, P. (2017) · Aging · doi:10.18632/aging.101194 · Cited by 42
PRC2 engages a bivalent H3K27M-H3K27me3 dinucleosome inhibitor
Diehl, K. L., Ge, E. J., Weinberg, D. N., Jani, K. S., Allis, C. D., & Muir, T. W. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911775116 · Cited by 41
Self-citationPlant, A., O’Halloran, K., & Goldman, S. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100777 · Cited by 41
Oncohistones: Exposing the nuances and vulnerabilities of epigenetic regulation
Mitchener, M. M., & Muir, T. W. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.07.008 · Cited by 41
Self-citationEpigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas
Sweha, S. R., Chung, C., Natarajan, S. K., Panwalkar, P., Pun, M. J., Ghali, A., Bayliss, J. M., Pratt, D. W., Shankar, A., Ravikumar, V., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf7860 · Cited by 41
Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies
Weisbrod, L. J., Anand, T., Vengoji, R., Shonka, N., Jain, M., Ho, W. S., Batra, S. K., & Salehi, A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216876 · Cited by 44
Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors
Fontebasso, A. M., Gayden, T., Nikbakht, H., Neirinck, M., Papillon‐Cavanagh, S., Majewski, J., & Jabado, N. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1325-8 · Cited by 40
Invited Review: Emerging functions of histone H3 mutations in paediatric diffuse high‐grade gliomas
Kasper, L. H., & Baker, S. J. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12591 · Cited by 40
Molecular markers and targeted therapy in pediatric low-grade glioma
de Blank, P. M. K., Fouladi, M., & Huse, J. T. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03529-1 · Cited by 41
H3.3K27M Mutation Controls Cell Growth and Resistance to Therapies in Pediatric Glioma Cell Lines
Rakotomalala, A., Bailleul, Q., Savary, C., Arcicasa, M., Hamadou, M., Huchedé, P., Hochart, A., Restouin, A., Castellano, R., Collette, Y., et al. (2021) · Cancers · doi:10.3390/cancers13215551 · Cited by 43
Exosome-based strategies for diagnosis and therapy of glioma cancer
Fath, M. K., Azami, J., Masoudi, A., Mosaddeghi-Heris, R., Rahmani, E., Alavi, F., Bahrami, A. A., Payandeh, Z., Khalesi, B., Dadkhah, M., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02642-7 · Cited by 40
Nguyen, K., Dobrowolski, C. N., Shukla, M., Cho, W., Luttge, B. G., & Karn, J. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010014 · Cited by 37
Jackson, E. R., Persson, M. L., Fish, C. J., Findlay, I. J., Mueller, S., Nazarian, J., Hulleman, E., van der Lugt, J., Duchatel, R. J., & Dun, M. D. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad144 · Cited by 38
Histone variants and cellular plasticity
Santoro, S. W., & Dulac, C. G. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.07.005 · Cited by 39
Kaye, E. C., Baker, J. N., & Broniscer, A. (2014) · CNS Oncology · doi:10.2217/cns.14.47 · Cited by 38
Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours
Haque, F., Varlet, P., Puntonet, J., Storer, L. C. D., Bountali, A., Rahman, R., Grill, J., Carcaboso, A. M., Jones, C., Layfield, R., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0449-1 · Cited by 38
Transcriptional and epigenetic mechanisms underlying astrocyte identity
Pavlou, M. A. S., Grandbarbe, L., Buckley, N. J., Niclou, S. P., & Michelucci, A. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.007 · Cited by 37
Surprising phenotypic diversity of cancer-associated mutations of Gly 34 in the histone H3 tail
Lowe, B. R., Yadav, R. K., Henry, R. A., Schreiner, P. A., Matsuda, A., Fernandez, A. G., Finkelstein, D., Campbell, M., Kallappagoudar, S., Jablonowski, C. M., et al. (2021) · eLife · doi:10.7554/elife.65369 · Cited by 37
A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis
Dhar, S., Gadd, S., Patel, P. A., Vaynshteyn, J., Raju, G. P., Hashizume, R., Brat, D. J., & Becher, O. J. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01336-5 · Cited by 38
Self-citationFranz, M., Payne, W. G., Xing, L., Naidu, D. K., Salas, R., Marshall, V. S., Trumpower, C., Smith, C. A., Steed, D. L., & Robson, M. C. (2008) · PubMed · Cited by 38
Pereira, K. N. E., Shan, J., Licht, J. D., & Bennett, R. L. (2023) · Biochemical Society Transactions · doi:10.1042/bst20210567 · Cited by 38
The cell-cycle choreography of H3 variants shapes the genome
Delaney, K., Weiss, N., & Almouzni, G. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.08.030 · Cited by 39
Identification of a peptide inhibitor for the histone methyltransferase WHSC1
Morrison, M. J., Boriack‐Sjodin, P. A., Swinger, K. K., Wigle, T. J., Sadalge, D., Kuntz, K. W., Scott, M. P., Janzen, W. P., Chesworth, R., Duncan, K. W., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197082 · Cited by 37
Potential application of cell reprogramming techniques for cancer research
Saito, S., Lin, Y., Nakamura, Y., Eckner, R., Wuputra, K., Kuo, K., Lin, C., & Yokoyama, K. K. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2924-7 · Cited by 38
Schramm, K., Iskar, M., Statz, B., Jäger, N., Haag, D., Slabicki, M. M., Pfister, S. M., Zapatka, M., Gronych, J., Jones, D., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz057 · Cited by 37
Sidoli, S., Lopes, M. D. C., Lund, P. J., Goldman, N., Fasolino, M., Coradin, M., Kulej, K., Bhanu, N. V., Vahedi, G., & Garcia, B. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-49894-4 · Cited by 37
Self-citationGlioma Stem Cells in Pediatric High-Grade Gliomas: From Current Knowledge to Future Perspectives
Da-Veiga, M.-A., Rogister, B., Lombard, A., Neirinckx, V., & Piette, C. (2022) · Cancers · doi:10.3390/cancers14092296 · Cited by 37
Metadata
- Authors
- Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D.
- Affiliations
- Rockefeller University (US)
- Princeton University (US)
- Duke University (US)
- University of Pennsylvania (US)
- Corresponding author
- Allis, C. David
- ORCID
- Venue
- Science
- Published
- 2013-05-17
- Volume
- 340
- Issue
- 6134
- Pages
- 857-861
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3951439
- OpenAlex
- W1995105508
- Cited by
- 1,345
- References
- 14
- Citations by year
- 2026: 73 · 2025: 82 · 2024: 103 · 2023: 106 · 2022: 103 · 2021: 118 · 2020: 146 · 2019: 112 · 2018: 84 · 2017: 102 · 2016: 90 · 2015: 95 · 2014: 87 · 2013: 40
- FWCI
- 51.21
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- National Institutes of Health (DP2OD007447)
- National Institute of Mental Health (P50MH096890)
- National Institute of General Medical Sciences (GM040922, R01GM107047, R01GM040922)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pediatric glioblastoma, diffuse intrinsic pontine glioma, H3K27M mutation, histone H3.3, H3K27me3, polycomb repressive complex 2, EZH2, histone methylation, gain-of-function mutations, epigenetic regulation
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Animals, Brain Neoplasms, Child, Glioblastoma, Histones, Humans, Lysine, Methionine, Methylation, Transgenes, Amino Acid Substitution, Mutation, Missense, Epigenesis, Genetic, Mice, HEK293 Cells, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
